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Treatment Practice and Research Issues in Improving 
Opioid Treatment Outcomes
Providers of treatment for opioid addiction have entered a new era of accountability, as Federal and
State regulators increasingly demand objective evidence of treatment effectiveness. Since the length of
treatment is associated with success of treatment, opioid treatment programs that demonstrate an
ability to retain patients can make a strong case that they are effective. The challenge to opioid treat-
ment providers is to examine their practices and begin organizational change to incorporate scientifi-
cally proven practices to improve patient retention. The challenge to the research community is to part-
ner more effectively with community-based providers to help them through the transition.
M
ay 18, 2001, was a landmark day in the history of what was once called methadone
maintenance treatment (MMT) or, more recently, opiate substitution (or replace-
ment) treatment. On that date, Federal oversight of MMT shifted from the Food and Drug
Administration, the Federal regulating authority since 1972, to the Substance Abuse and
Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Treatment
(CSAT) (DHHS, 2001). The main objective of the change in oversight is to move programs
toward stricter accountability for patient outcomes, such as decreased drug use, reduced
criminal behavior, and improved social functioning. Increasingly, programs will need to do
more to maintain their licenses than simply adhere to the regulations governing the deliv-
ery of methadone, LAAM, and other medications for treating opioid addiction. They
also will have to demonstrate that they measure and meet criteria for acceptable levels of
treatment effectiveness and patient benefit.
The new rules also give providers more flexibility to adopt scientifically validated out-
come-enhancing practices. To reflect the emphasis on a variety of potentially effective prac-
tices that go beyond methadone maintenance, SAMHSA has instituted the label “opioid
treatment program” (OTP).
This article offers an OTP director’s perspective on how programs can succeed in the
new era. OTPs must draw on scientific research, which has provided a wealth of studies
to inform clinical practice. A key principle that has emerged is that the length of time a
patient stays in treatment (“retention”) is a highly significant indicator of program quality;
measured repeatedly, it is a tool for assessing progress in improving outcomes. 
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To achieve and document greater patient retention as
well as other desirable patient outcomes, many OTPs
will need to make sometimes far-reaching changes in
their operations and offerings. Collaboration between
providers and researchers will be essential to solving
the many practical problems OTPs must overcome to
fully implement science-based treatments.
PATIENT RETENTION: WHAT RESEARCH
SHOWS
There is clear and abundant evidence that longer dura-
tion of treatment is associated with better patient out-
comes (see Figure 1), both during methadone main-
tenance and after successful completion of treatment
(that is, gradual tapering from methadone with psy-
chosocial stability and no return to opioid addiction)
(Ward et al., 1998). The studies suggest that treatment
should last no less than 1 year, and that 2 or 3 years of
treatment produces superior outcomes. No studies
support setting a fixed limit on duration of treatment.
Thus, patient retention is a key performance indica-
tor for OTPs to routinely measure and evaluate, and
taking steps to increase patient retention is a poten-
tially valuable strategy for improving patient outcomes.
Researchers have studied a number of patient-
related and program-related factors to see whether they
affect retention of patients in treatment. Patient-related
factors include age, race, ethnicity, sex, the number of
substances abused, psychopathology, employment,
social support network, and level of motivation to quit
drugs. Findings about which of these factors affect
retention have been mixed; but even if there were clear
findings, they would be of little practical help to providers
seeking to improve retention and outcomes. For both
practical and ethical reasons, OTPs cannot select for
admission only those applicants whose characteristics
indicate a higher probability of success in treatment.
OTPs, then, must look to program-related fac-
tors for opportunities to make changes that will improve
their patients’ outcomes. Among the factors that can
enhance success, according to studies, are:
• Use of individually determined methadone doses
and higher doses (≥60 mg) (Maddux et al., 1997);
• Individualized treatment plans that identify needs
for employment, family, legal, financial, and other
supplemental services (Joe et al., 1991) and access
to such services (Condelli, 1993);
• Use of contingency contracting with negative incen-
tives (for example, treatment sanctions; Saxon et al.,
1996) or positive incentives (such as medication
take-home privileges; Chutuape et al., 1999) linked
to urinalysis results and attendance at dosing and
counseling sessions;
• Counselor behaviors and ability to form a working
alliance with patients (Blaney and Craig, 1999);
• Staff acceptance of the philosophy of maintenance
treatment, which sees opioid addiction as a medical
illness that requires medication and counseling for
an indefinite period (Caplehorn et al., 1998);
• Frequency of counseling contacts and other program
features (Magura et al., 1999); and 
• Greater experience and involvement with treatment
on the part of the OTP director (Magura et al., 1999).
IMPLEMENTING NEW PRACTICES:
OBJECTIVES AND BARRIERS
Key research-proven objectives that OTPs can adopt
to improve patient retention and other outcomes
include acquiring research information; identifying
cost-effective research-based interventions; securing
high-quality social services; and tracking retention
rates. As they pursue these objectives, OTPs will
encounter practical barriers in the areas of resources
and staffing. They will also face information gaps where
research to date has not provided key answers and
where implementation-oriented research will be crit-
ical to an efficient transition to more effective treat-
ment.
Learning to acquire, evaluate, and use research
will be a necessary first task for many OTPs. In this
author’s experience, OTP managers and their staffs
are largely unaware of specific research findings on
the relationship of treatment variables to retention
and outcomes. As knowledge is an important element
of change, the research community and leaders in OTP
associations could do a better job of disseminating
findings to the treatment community. CSAT’s Treatment
Improvement Protocol (TIP) series, NIDA’s “Blending
Research and Practice” meetings, this new NIDA jour-
nal, and the training efforts of the national network
of Addiction Technology Transfer Centers (ATTCs)
are examples of a good start in that direction. However,24 • SCIENCE & PRACTICE PERSPECTIVES—JULY 2002 
many programs do not take advantage of those resources.
Furthermore, OTP managers who do inform them-
selves must also facilitate knowledge dissemination to
their staffs. 
Having reviewed the literature linking program
characteristics to retention, an OTP manager may be
able to identify several ways to modify or enhance a
program to improve outcomes. At this juncture, an
important objective will be to select for implementa-
tion those that use the OTP’s resources cost-effec-
tively—in other words, that are worth the investment.
This decision can be difficult, in part because researchers
have tended to test interventions without sufficient
attention to the resource limitations of OTPs. For
example, one research project found that a take-home
incentive program—granting take-home privileges to
patients who reduce their drug use—had a positive
effect on outcomes (Chutuape, 1999); however, the
resources devoted to the study were greater
than most OTPs enjoy. No estimate was
made of how much an agency might need
to spend to implement and sustain a take-
home incentive program, or whether such
a program might yield a better return on
the investment of agency resources than,
say, training and supervising counselors
to be more proficient in the use of moti-
vational interviewing. More research focus
on the cost-effectiveness of various inter-
ventions or staff training strategies would
be extremely valuable.
Once an OTP director has selected
a science-based intervention or program
component for implementation, staff
training will be critical for success. This
is another area, however, in which research
has not yet provided OTP managers with
much guidance. If, for example, an OTP
manager, recognizing the counselor’s
important role in improving patient reten-
tion, wished to improve staff skills in the
use of motivational interviewing, how
would that best be accomplished? What
kind of training, delivered by a trainer
with what qualifications, would yield the
highest probability of skills acquisition
and incorporation of those skills in clin-
ical practice? Scientific research to help
managers resolve some of these questions
would be very welcome.
Scientific research has shown that outcomes
improve when individualized treatment plans match
service delivery to individual patients’ needs and appro-
priate high-quality social services are provided. In
attempting to meet this objective, OTPs will again
confront issues of developing and allocating resources
and effecting organizational change.
With resources limited by low reimbursement
rates, many OTPs look to their communities for qual-
ity health and social services for their patients.
Unfortunately, many communities and social serv-
ice providers view OTPs and their patients with antipa-
thy or disdain. Often, they misunderstand opiate ago-
nist therapy, consider OTPs little more than legalized
drug dealers, and consequently want nothing to do
with an agency or its patients. In addition, many social
service providers seem to view heroin addiction as
FIGURE 1. Time in Treatment and Daily Opioid Use in Year 
Following Discharge
Duration of treatment is a key measure for assessing the quality of a treatment 
program because it is directly related to successful outcomes. In a study with 3,248
patients, daily opioid use in the year following discharge from treatment declined
in direct proportion to the length of time patients stayed in treatment, regardless
of the treatment modality—therapeutic community, outpatient drug-free, or meth-
adone maintenance. Patients who simply underwent detox without followup treat-
ment had the poorest outcomes. Decreased criminal behavior showed a similar
direct relationship to length of treatment.
Source: Simpson and Sells, 1982.
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privileges), clinical practice constraints (for example,
limited counseling sessions per patient per month),
as well as internal policies and procedures growing out
of the philosophies of administration and staff. This
history has ingrained attitudes and responses among
program managers and staffs that will require spe-
cial effort to change. OTPs and their staffs—much
like the patients they treat—approach the change
process with different strengths and challenges (D’Aunno
et al., 1999).
ADMINISTRATIVE DISCHARGE:
TROUBLING ISSUES
As an OTP director, this writer could improve his
agency’s retention rate with the stroke of a pen, by
eliminating the possibility of administrative discharge
(expulsion for cause) from treatment. Administrative
discharge clearly lowers retention rates, but just as
clearly is necessary in some cases. Moreover, while
research and improved treatments may be able to pro-
vide standards for some types and causes of adminis-
trative discharge, others seem likely to remain mat-
ters of difficult—and ethically troubling—judgment.
Unremitting cocaine use by patients in OTPs
is one of the most common causes of administrative
discharge as well as dropout from treatment (Magura
et al., 1998). Developing specialized, cost-effective
therapies for cocaine-using methadone patients would
help improve retention.
The most difficult administrative discharge deci-
sions involve lack of response to treatment. While pro-
gram rules often cite noncompliance rather than non-
response as the reason for discharge, in effect they
define what the program deems to be nonresponse.
In an ideal world, there would be no need for such
rules. OTPs would have the resources to take all
who sought treatment and let patients continue indef-
initely as long as they participated, even minimally,
and did not impede the recovery of others. As things
stand, however, with limited public funding and statu-
tory caps on treatment “slots,” an OTP manager must
weigh keeping a poorly responding patient in treat-
ment against providing treatment access to someone
else who might be able to benefit more from what the
program offers.
In this environment, science can help clinicians
make more informed decisions about who should stay
and who should go. Currently, agency managers and
the staff determine what constitutes nonresponse sub-
an intractable condition brought on by willful mis-
conduct and so reject or give lowest priority to patients
referred by OTPs. The research community has in
recent years publicized the effectiveness of opioid
addiction therapy, encouraging the public to correctly
characterize opioid addiction as a chronic medical dis-
order. In some areas this activity has led to signifi-
cantly better acceptance of OTPs and their patients.
Sadly, much work remains.
To evaluate its strategy for improving outcomes
and to set goals for continuing improvement, an OTP
must measure patient retention and monitor how it
changes over time. Many OTPs cannot currently
accomplish such measurements and will need to redesign
their patient data systems to obtain and record all the
necessary information on patient characteristics as
well as the type and amount of treatment delivered to
each. Many OTPs also will want to convert to a com-
puterized patient information system to be able to
analyze information easily and quickly. These are
daunting organizational tasks that entail significant
costs—both financial resources and staff time. Some
State governments assist OTPs in their data acquisi-
tion and analysis, others do not. The research com-
munity could make an invaluable contribution by
equipping agency and statewide data systems with the
ability to perform survival analysis, the key statistical
technique for measuring and comparing rates of reten-
tion (Magura et al., 1998).
Two other practical issues face OTPs preparing
for programmatic change: lack of implementation
manuals and lack of expertise in organizational change.
The shortage of practical implementation manuals—
for example, guidance for how to start up and run a
take-home incentives program, including quality assur-
ance guidelines—is a barrier to change but one the
research community could address by ensuring cre-
ation and dissemination of such documents once an
intervention has been validated in studies. Development
of such materials should be one of the requirements
for funding of research studies.
OTP managers have a wide range of experi-
ence and expertise and now face a sea change in expec-
tations for the operation of their programs. Many
could benefit from guidance on effective ways to pre-
pare for and implement organizational change.1 For
30 years, OTPs have struggled to comply with mul-
titudinous regulations and local laws (such as limits
on dose levels, length of treatment, and take-home
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together the perceived benefits and barriers to change.
This means, in short, taking a fearless inventory of
the strength and weaknesses of each agency.
In my own case, the inventory of my agency’s
practices and assets revealed that our intake assess-
ment form, developed some years earlier, was not
going to be adequate. We switched to the Addiction
Severity Index (ASI), a standardized assessment
instrument (available free at www.tresearch.org
/Assessment%20Inst/instruments.htm) that allows us
to measure our retention rates and compare them
to our past performance and to other programs using
the ASI. The ASI also facilitates initial treatment
plans that focus on patients’ needs for services in a
variety of life domains, not just their drug addic-
tion. 
• Focus on data. Read the literature about program
factors that affect retention and outcome, and exam-
ine your agency practices in that light. Decide what
data you need to collect for the ongoing program
evaluation and quality assurance necessary to improve
outcomes. Take the necessary steps to collect those
data into a computerized database. Commit to a
serious, ongoing allocation of agency resources for
staff training and supervision.
In our agency, we have trained our intake coun-
selors to gather the ASI information on all incom-
ing patients and enter it in an electronic database
that I then use in continuous program evaluation
to examine patient characteristics, including their
service needs, how those characteristics and needs
change over time, and response to services. The cost
to my agency was for staff training and acquisition
of computers and the ASI software.
• Partner with researchers.Reach out to the research
community for help with decisionmaking on data
acquisition and for ongoing data analysis. The
collaboration will help you to better define and
answer questions about how you can improve out-
comes for your patients. All of us learned most, if
not all, of what we know about clinical practices
from listening to our patients. Think of program
evaluation as a more systematic way of listening to
your patients.
Through partnering with research colleagues to
conduct studies at my agency, our staff has learned
more about what kinds of behavioral interven-
jectively, from their clinical perspectives. OTPs would
benefit enormously if research could provide ways
to make these decisions objectively, by identifying
signs—for example, levels of continuing drug use,
absences from dosing and counseling sessions, lack of
progress toward treatment goals—that continuing
treatment will probably be fruitless. Such data would
also help OTPs advocate for increased funding and
treatment options, such as low-threshold treatment
programs that provide options other than expulsion
for lack of response. Research could also help OTPs
by investigating how the presence of nonresponders
affects the therapeutic environment for other patients—
another concern that managers weigh when consid-
ering administrative discharges.
Clearly, for programs to be viable, some limits
for acceptable behavior must be set and enforced.
However, whether a particular behavior is unaccept-
able can be difficult to judge. OTPs generally con-
cur that behaviors that threaten the safety of patients
and staff and the status of the program in the com-
munity warrant expulsion, and they agree that vio-
lence or threats of violence against patients (on agency
premises) or staff (on or off agency premises) and drug
dealing fall into this category. Yet whether a particu-
lar act constitutes threatening behavior or drug
dealing can be debatable. It is hard to imagine science
lending any guidance to these judgments.
RECOMMENDATIONS TO CLINICAL
COLLEAGUES
We stand at the threshold of a new era in the treat-
ment of opioid addiction. Not only is methadone treat-
ment changing, but new medications will soon be
available for deployment in a variety of ways, not just
in traditional clinic-based settings. We will be more
accountable for outcomes than ever before. Patients,
their families, our communities, and funding agen-
cies will ask not whether opioid treatment is effective,
but how well our patients do. Some of us will rise to
the challenges of the new era and thrive; some won’t.
In this writer’s opinion, three steps are critical:
• Embrace change.We have to change both our think-
ing and our practices, beginning with a conversation
between managers and staffs. Agency administrators
will need to understand the new environment and
engage their staffs in a dialogue about the reasons to
change and methods of change and then explore
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• Develop implementation and quality assurance
manuals. Using your experience as study design-
ers and implementers, generate manuals to guide
OTPs through the process of implementing state-
of-the-art clinical interventions and practical self-
evaluation protocols.
• Develop “best practice” benchmarks for patient
retention and outcomes. Help OTPs, their regula-
tors, and funders understand what optimal clinical
performance looks like so that they might meas-
ure program performance against those standards.
This will require refining and applying the tech-
niques, called case-mix adjustment, used in per-
formance comparisons to make allowance for the
fact that populations in some programs are more
difficult to treat than others. Comparisons of out-
comes made without taking into account the rela-
tive difficulties of treatment populations can lead
to erroneous conclusions and unwarranted reac-
tions, such as personnel actions or program fund-
ing cuts or decertification. 
NOTE
1 Readers interested in a guidebook for organizational
change in addiction treatment programs could refer
to The Change Book: A Blueprint for Technology Transfer,
produced and distributed by the National ATTC,
which can be reached at 1-877-652-2882 or
www.nattc.org.
CORRESPONDENCE
Ron Jackson, Evergreen Treatment Services, 1700
Airport Way South, Seattle, WA 98134; e-mail:
ronjack@u.washington.edu.
tions work with our patients, and clinical person-
nel are better able to apply those interventions.
Participation in research has brought financial assets
to my agency and allowed us to attract and retain
very capable clinicians.
RECOMMENDATIONS TO RESEARCH
COLLEAGUES
The new emphasis on program evaluation and qual-
ity assurance in OTPs affords a rare opportunity for
collaboration between clinical practitioners and
researchers interested in treatment improvement. This
is the era when research-to-practice can really deliver
on its heretofore unrealized promise. What is the
research community to do to help make this happen?
Here are four steps to accomplishing that goal:
• Stop doing independent studies on the effective-
ness of methadone treatment.If the new CSAT reg-
ulations work as designed, this country will have
hundreds of OTPs systematically gathering data and
evaluating their programs’ clinical outcomes. Partner
with OTPs to design and conduct collaborative stud-
ies to refine the analysis of the treatment factors that
we know contribute to retention and patient out-
come and to identify additional treatment variables
that affect outcomes. The power of the data being
collected by OTPs will also allow analysis of gen-
der-specific treatment variables that affect retention
and outcomes.
• Study cost-effectiveness.While studies have shown
mixed results with respect to the amount of variance
in patient outcomes attributable to program vari-
ables, OTPs want and need to know which program
variables offer the best return on investment to
improve outcomes. For example, given its financial
constraints, should a program devote funds to more
frequent urinalyses and incorporation of results in
treatment planning, or should it spend that money
on developing counselor competencies?28 • SCIENCE & PRACTICE PERSPECTIVES—JULY 2002 
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Lorraine Collins:The demand for accountability is
ratcheting up. Methadone programs may find them-
selves having to be increasingly accountable.
William Cornely:With respect to retention of patients
in opioid treatment, most drug-free programs have
already made the transition to viewing the patient as
a customer who must be retained, and their experi-
ence may be helpful to methadone programs.
What other outcomes, besides retention, should
be considered for accountability? For example, what
about having someone off methadone in a year or 
2 years, or having lower incidence of AIDS?
Christine Grella: Ideally, methadone programs would
target a range of outcomes, including use of opioids
and other drugs, alcohol use, and then issues such as
housing, unemployment, and general psychosocial
functioning. A troubling issue that I saw first-hand
while working on a study in a methadone clinic is that
much of the patients’ ability to respond to treatment
was related to issues in their communities and to things
like whether they continued to live with a substance
abuser. These environmental issues are a huge deter-
minant of outcomes and completely beyond our 
control.
Grella: Jackson’s call for partnership—informing the
treatment staff of current research and inviting researchers
to work with providers in testing different approaches
to improving delivery of treatment—is excellent.
He is absolutely right, too, in saying we need more
research on how organizations can change to imple-
ment different treatment practices. A potential research
question would be, ‘What program characteristics are
associated with the ability to implement effective prac-
tices?’ Jackson cites one example: a study showing that
attitudes and experiences of program directors in
methadone programs made a difference.
Collins: Many programs have staff members who work
there because of their experiences recovering from sub-
stance abuse and who have an understandable bias
toward whatever treatment regimen was successful for
RESPONSE: THE NEW ENVIRONMENT OF ACCOUNTABILITY 
FOR OTPS
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researchers
work with
treatment
providers, our
methods have to
be objective,
but we also
want the treat-
ment to be suc-
cessful, and
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